本文關(guān)鍵詞：骨質(zhì)疏松癥的腎素-血管緊張素系統(tǒng)發(fā)生機制及治療靶點研究進展　出處：《中國藥理學(xué)與毒理學(xué)雜志》2016年10期 　論文類型：期刊論文

  更多相關(guān)文章： 腎素-血管緊張素系統(tǒng) 骨質(zhì)疏松癥 骨代謝

【摘要】：骨質(zhì)疏松癥(OP)是一種骨代謝疾病,表現(xiàn)為骨形成減少和骨吸收增加,導(dǎo)致骨量丟失、骨組織微結(jié)構(gòu)破壞,全身各處易于骨折。骨組織局部可表達腎素-血管緊張素系統(tǒng)(RAS)的主要成分并通過經(jīng)典及非經(jīng)典途徑參與細胞氧化應(yīng)激、增殖、分化及凋亡等過程。骨組織局部RAS過度激活時,一方面可以抑制成骨細胞分化或直接損傷其骨形成功能,另一方面促進破骨細胞分化和成熟,二者共同導(dǎo)致骨形成減少、骨吸收增加,參與OP發(fā)生。RAS抑制劑包括腎素抑制劑、血管緊張素轉(zhuǎn)換酶抑制劑和血管緊張素Ⅱ受體拮抗劑,已經(jīng)被證實可以有效地拮抗RAS慢性激活時產(chǎn)生的病理效應(yīng),因此被認為是治療OP的候選藥物之一。
[Abstract]:Osteoporosis (Osteoporosis) is a kind of bone metabolic disease, which is characterized by reduced bone formation and increased bone resorption, resulting in loss of bone mass and destruction of bone microstructure. Bone tissue can express the main components of renin-angiotensin system (Ras) and participate in cell oxidative stress and proliferation through classical and non-classical approaches. During the process of differentiation and apoptosis, local RAS can inhibit the differentiation of osteoblasts or directly damage the bone formation function, on the other hand, promote the differentiation and maturation of osteoclasts. Both of them lead to decrease of bone formation and increase of bone resorption. Ras inhibitors include renin inhibitor angiotensin converting enzyme inhibitor and angiotensin 鈪，

本文編號：1437252